Tisotumab vedotin in recurrent or metastatic cervical cancer

被引：23
作者：
Bogani, Giorgio [1 ]
Coleman, Robert L. [2 ]
Vergote, Ignace [3 ]
Raspagliesi, Francesco [1 ]
Lorusso, Domenica [4 ]
Monk, Bradley J. [5 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Univ Hosp Leuven, Leuven, Belgium
[4] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy
[5] Creighton Univ, Univ Arizona, HonorHlth, Phoenix, AZ USA
来源：
CURRENT PROBLEMS IN CANCER | 2023年 / 47卷 / 03期
关键词：
Tisotumab vedotin; Cervical cancer; Survival; Immunotherapy; ADC; ANTIBODY-DRUG CONJUGATE; PREVIOUSLY TREATED RECURRENT; TISSUE FACTOR; CYTOPLASMIC DOMAIN; BEVACIZUMAB; INSIGHTS; VIIA;
D O I：
10.1016/j.currproblcancer.2023.100952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Tisotumab vedotin (TV) is an antibody-drug conjugate used for the treatment of adult patients with re-current or metastatic cervical cancer. TV comprised of a monoclonal antibody against tissue factor and monomethyl auristatin E (MMAE), a potent inhibitor of cell division. The innovaTV-201 and innovaTV-204/GO30xx/ENGOT-cx6 trials showed that TV has clinically meaningful and durable antitumor activity in pretreated patients with recurrent or metastatic cervical cancer. The innovaTV-204 trial showed that TV monotherapy resulted in an objective response rate of 24% (including 7% and 17% complete and par-tial responses, respectively). In September 2021, the US Food and Drugs Administration (FDA) granted accelerated approval to TV for the treatment of recurrent or metastatic cervical cancer patients with disease progression on or after chemotherapy. The ongoing randomized, open-label Phase 3 innovaTV-301/ENGOTcx12/GOG-30xx trial will assess the effect of TV in pre-treated recurrent or metastatic cervical cancer. Meanwhile, the phase 1b/2 trial ENGOT Cx8/GOG 3024/innovaTV-205 is testing other possible com-bination between TV and other treatments. TV is characterized by a promising antitumor activity and an acceptable safety profile. Moreover, the preliminary data highlighted the feasibility of using TV in first line. In the first line, TV in combination with carboplatin or pembrolizumab provides an ORR of 55% and 41%, respectively Although the effect of adding TV to the current standard of care in first-line (carboplatin plus pembrolizumab) is still under evaluation, we expected to observe impressive results in the cervical cancer population.
引用
收藏
页数：13
相关论文
共 35 条
[21]   Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer [J].
Landoni, F ;
Maneo, A ;
Colombo, A ;
Placa, F ;
Milani, R ;
Perego, P ;
Favini, G ;
Ferri, L ;
Mangioni, C .
LANCET, 1997, 350 (9077) :535-540
[22]   Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways [J].
Liu, Yingmei ;
Mueller, Barbara M. .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 344 (04) :1263-1270
[23]  
Lorusso D, 2022, J CLIN ONCOL, V40
[24]   TISOTUMAB VEDOTIN (TV) plus BEVACIZUMAB OR PEMBROLIZUMAB OR CARBOPLATIN IN RECURRENT/METASTATIC CERVICAL CANCER (R/MCC): PHASE 1B/2 ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY DOSE-ESCALATION RESULTS [J].
Monk, B. ;
Van Gorp, T. ;
Lorusso, D. ;
O'Cearbhaill, R. Eilish ;
Westermann, A. ;
Banerjee, S. ;
Collins, D. ;
Klat, J. ;
Madsen, K. ;
Baurain, J-F ;
Jackson, A. ;
Boere, I. ;
Pignata, S. ;
Gort, E. ;
Moroney, J. ;
Soumaoro, I. ;
Andreassen, Cm ;
Nicacio, L. ;
Gennigens, C. ;
Vergote, I. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 :A7-A8
[25]   Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study [J].
Monk, Bradley J. ;
Sill, Michael W. ;
Burger, Robert A. ;
Gray, Heidi J. ;
Buekers, Thomas E. ;
Roman, Lynda D. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1069-1074
[26]  
NIH Library, ABOUT US
[27]   Tissue factor cytoplasmic domain stimulates migration by activation of the GTPase Rac1 and the mitogen-activated protein kinase p38 [J].
Ott, I ;
Weigand, B ;
Michl, R ;
Seitz, I ;
Sabbari-Erfani, N ;
Neumann, FJ ;
Schömig, A .
CIRCULATION, 2005, 111 (03) :349-355
[28]   The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer [J].
Pignata, Sandro ;
Scambia, Giovanni ;
Lorusso, Domenica ;
De Giorgi, Ugo ;
Nicoletto, Maria Ornella ;
Lauria, Rossella ;
Mosconi, Anna Maria ;
Sacco, Cosimo ;
Omarini, Claudia ;
Tagliaferri, Pierosandro ;
Ferrandina, Gabriella ;
Cinieri, Saverio ;
Savarese, Antonella ;
Valabrega, Giorgio ;
Pisano, Carmela ;
Salutari, Vanda ;
Raspagliesi, Francesco ;
Kopf, Barbara ;
Cecere, Sabrina Chiara ;
Amadio, Giulia ;
Maltese, Giuseppa ;
Di Napoli, Marilena ;
Greggi, Stefano ;
Signoriello, Simona ;
Daniele, Gennaro ;
Sacco, Alessandra ;
Losito, Simona ;
Normanno, Nicola ;
Perrone, Francesco ;
Gallo, Ciro ;
Piccirillo, Maria Carmela .
GYNECOLOGIC ONCOLOGY, 2019, 153 (03) :535-540
[29]   Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies [J].
Seidel, Ursula J. E. ;
Schlegel, Patrick ;
Lang, Peter .
FRONTIERS IN IMMUNOLOGY, 2013, 4
[30]   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249
1234